Baseline patient characteristics
| . | M3 . | M3V . | P . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| I0129 (n = 150) . | LPA96 (n = 145) . | LPA99 (n = 453) . | All (n = 748) . | I0129 (n = 24) . | LPA 96 (n = 30) . | LPA 99 (n = 101) . | All (n = 155) . | ||
| Median age, y (range) | 37 (1-81) | 42 (2-78) | 40 (2-83) | 40 (1-83) | 36 (5-76) | 40 (12-71) | 39 (3-79) | 39 (3-79) | .51 |
| Male, n (%) | 71 (47) | 87 (60) | 216 (48) | 374 (51) | 11 (46) | 16 (53) | 50 (53) | 77 (50) | .93 |
| WBC, median (range) | 1.8 (0.3-95.2) | 1.5 (0.3-148.0) | 1.8 (0.2-460) | 1.8 (0.2-460) | 5.8 (0.6-550) | 19.8 (1.4-210) | 15.9 (0.7-188.5) | 15.8 (0.6-550) | < .0001 |
| Platelets, median (range) | 36.5 (5-246) | 20 (1-161) | 22 (1-207) | 24 (1-246) | 36 (6-123) | 19.5 (4-146) | 22 (1.8-207) | 23 (1.8-207) | .52 |
| Hemoglobin, median (range) | 9.5 (2.9-16.4) | 9.5 (4.4-12.8) | 8.9 (3.0-15.3) | 9.2 (2.9-16.4) | 9.6 (2.1-13.2) | 9.1 (4.3-15.2) | 10.0 (4.4-16.9) | 9.8 (2.1-16.9) | .0005 |
| Relapse risk, n (%) | < .0001 | ||||||||
| Low | 56 (37) | 31 (21) | 94 (21) | 181 (24) | 8 (33) | 3 (10) | 12 (12) | 23 (15) | |
| Intermediate | 72 (48) | 91 (63) | 284 (63) | 447 (60) | 7 (29) | 6 (20) | 25 (25) | 38 (25) | |
| High | 22 (15) | 23 (16) | 75 (17) | 120 (16) | 9 (38) | 21 (70) | 64 (64) | 94 (61) | |
| RAS, n (%) | 43 (29) | 41 (28) | 102 (23) | 186 (25) | 1 (4.2) | 40 (31) | 40 (31) | 41 (26) | .66 |
| CR rate, % | 80* | 92 | 92 | 89* | 79* | 77 | 84 | 82* | .004 (.64)† |
| Follow-up time among survivors, median (range) | 11.9 (0.6-14.3) | 10.6 (9.4-12) | 6.4 (3.5-9) | 7.6 (0.6-14.3) | 10.9 (4.3-14.5) | 10.6 (9.7-12.1) | 6.9 (3.6-9.3) | 7.6 (3.6-14.5) | .34 |
| . | M3 . | M3V . | P . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| I0129 (n = 150) . | LPA96 (n = 145) . | LPA99 (n = 453) . | All (n = 748) . | I0129 (n = 24) . | LPA 96 (n = 30) . | LPA 99 (n = 101) . | All (n = 155) . | ||
| Median age, y (range) | 37 (1-81) | 42 (2-78) | 40 (2-83) | 40 (1-83) | 36 (5-76) | 40 (12-71) | 39 (3-79) | 39 (3-79) | .51 |
| Male, n (%) | 71 (47) | 87 (60) | 216 (48) | 374 (51) | 11 (46) | 16 (53) | 50 (53) | 77 (50) | .93 |
| WBC, median (range) | 1.8 (0.3-95.2) | 1.5 (0.3-148.0) | 1.8 (0.2-460) | 1.8 (0.2-460) | 5.8 (0.6-550) | 19.8 (1.4-210) | 15.9 (0.7-188.5) | 15.8 (0.6-550) | < .0001 |
| Platelets, median (range) | 36.5 (5-246) | 20 (1-161) | 22 (1-207) | 24 (1-246) | 36 (6-123) | 19.5 (4-146) | 22 (1.8-207) | 23 (1.8-207) | .52 |
| Hemoglobin, median (range) | 9.5 (2.9-16.4) | 9.5 (4.4-12.8) | 8.9 (3.0-15.3) | 9.2 (2.9-16.4) | 9.6 (2.1-13.2) | 9.1 (4.3-15.2) | 10.0 (4.4-16.9) | 9.8 (2.1-16.9) | .0005 |
| Relapse risk, n (%) | < .0001 | ||||||||
| Low | 56 (37) | 31 (21) | 94 (21) | 181 (24) | 8 (33) | 3 (10) | 12 (12) | 23 (15) | |
| Intermediate | 72 (48) | 91 (63) | 284 (63) | 447 (60) | 7 (29) | 6 (20) | 25 (25) | 38 (25) | |
| High | 22 (15) | 23 (16) | 75 (17) | 120 (16) | 9 (38) | 21 (70) | 64 (64) | 94 (61) | |
| RAS, n (%) | 43 (29) | 41 (28) | 102 (23) | 186 (25) | 1 (4.2) | 40 (31) | 40 (31) | 41 (26) | .66 |
| CR rate, % | 80* | 92 | 92 | 89* | 79* | 77 | 84 | 82* | .004 (.64)† |
| Follow-up time among survivors, median (range) | 11.9 (0.6-14.3) | 10.6 (9.4-12) | 6.4 (3.5-9) | 7.6 (0.6-14.3) | 10.9 (4.3-14.5) | 10.6 (9.7-12.1) | 6.9 (3.6-9.3) | 7.6 (3.6-14.5) | .34 |